Bio-link Australia Pty. Ltd.


Please find below a list of selected recent news and press releases from Bio-Link, our clients and the industry. Please select a specific news list for each source from the buttons on the left hand side.

10th July 2017 – First Dosing in a Phase 1b Combination Trial of the Dynamin Inhibitor Prochlorperazine and Anti-EGFR Monoclonal Antibody Cetuximab in Head and Neck Squamous Cell Carcinoma Patients.

The first two patients have been dosed in a phase Ib clinical trial at the Princess Alexandra Hospital (PAH, Brisbane, Australia), evaluating the efficacy of co-treatment of the anti-psychotic / anti-emetic drug prochlorperazine (Stemetil®) with anti-EGFR monoclonal antibody (mAb) cetuximab in head and neck squamous cell carcinoma (HNSCC) patients (HREC/16/QPAH/825). Prochlorperazine is a potent off-target inhibitor of the enzyme dynamin II. To learn more, please click here.

7th May 2017 – Oncology Venture – New APO010 multiple myeloma trial initiation

Oncology Venture, a precision oncology biopharmaceutical company and Bio-Link client, has recently announced important milestones in the development of its phase I/II immuno-oncology drug candidate APO010, granting of a key US patent for phase II ready drug candidate irofulven, and validation of its platform precision medicine technology, Drug Response Predictor™ (DRP™):

  • The first multiple myeloma patient was treated with APO010 in a phase 1/2 trial, by utilising the proprietary APO010 DRPTM companion diagnostic to select highly likely responders. Read more
  • Oncology Venture’s successful patent strategy is evident through a recently granted US patent covering the DRPTM and Irofulven. Irofulven is a potent anti-cancer drug candidate that will be tested in a focused phase 2 trial in likely patient responders with castration-resistant prostate cancer. Read more
  • The predictive power of the DRPTM was the topic of Oncology Venture’s recent ASCO poster presentation, demonstrating that it successfully predicts response to epirubicin, one of the most used breast cancer treatments. The DRPTM was significantly associated with Progression Free Survival (PFS) in a cohort of 135 metastatic breast cancer patients. Read more

oncology venture logo-1

8th May 2017 – Bio-Link Survey: Antibody(-like) Therapeutics in Australia


Bio-Link is engaged by a client to scout for Australian therapeutics programs with antibodies and antibody-like drugs. All stages of development are considered, both within academia (e.g. Garvan Institute’s Centre for Targeted Therapies) and industry (e.g. CSL). The scouting results are likely to be shared with the global pharma industry, which might boost commercial R&D activities in Australia. Names of research groups or companies can be submitted below.
Thanks for your input!

Organisation Details

Name of Research Groups and/or Companies:
Technology/Program Specifics:

Bio-Link Australia Pty Ltd ,
Suite 6/98 Glebe Point Road, Glebe, New South Wales, 2037
Level 2, Birdwood Offices, 19 Prospect Street, Box Hill, Victoria, 3128


23rd May 2017 – Bio-Link Engaged by Kunovus Technologies

Bio-Link has been engaged by Kunovus Technologies to facilitate partnering of KT009, a preclinical, intra-intervertebral disk-administered regenerative biological therapy for the treatment of degenerative disk disease and chronic back pain. Kunovus Technologies has compelling preclinical data supporting KT009-mediated disk regeneration and subsequent reduction in pain. KT009 is poised to enter GMP manufacturing and formal preclinical assessment prior to clinical evaluation.

To learn more about this partnering opportunity, please click here.

Kunovus Technologies

16th May 2017 – Bio-Link Engaged by Actinogen Medical

Bio-Link has been engaged by Actinogen Medical to facilitate partnering of Xanamem™,a phase II, first-in-class, orally active, brain penetrant, potent and selective 11β-HSD1 inhibitor; designed to reduce regeneration of cortisol within the brain. Today, Actinogen Medical has announced treatment of the first patient in a global phase II clinical study investigating Xanamem™ for the treatment of Alzheimer’s disease.

To learn more about this partnering opportunity, please click here.